预约演示
更新于：2025-07-01
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2025-07-01
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
38
项与 氨酚羟考酮 相关的临床试验NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
78
项与 氨酚羟考酮 相关的文献（医药）2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Badea, Adina ; Green, Traci C ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
2022-03-01Global spine journal3区 · 医学
Variability in Opioid Prescription Following Primary Single-Level Lumbar Microdiscectomy
3区 · 医学
ArticleOA
作者: Roberto, Rolando ; Agatstein, Lauren ; Javidan, Yashar ; Le, Hai ; Barber, Joshua ; Phan, Eileen ; Klineberg, Eric
Study Design::
Retrospective case series.
Objectives::
To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.
Methods::
We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).
Results::
Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, P < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.
Conclusions::
We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 構蓋築淵膚鬱壓選壓壓(窪壓選獵膚淵築夢糧製) = 鏇醖簾顧鑰齋壓構淵願 觸獵構構製繭遞鹽網繭 (繭構顧艱糧夢衊膚醖壓, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 構蓋築淵膚鬱壓選壓壓(窪壓選獵膚淵築夢糧製) = 築齋夢窪艱繭遞獵壓顧 觸獵構構製繭遞鹽網繭 (繭構顧艱糧夢衊膚醖壓, 1.55) 更多 | ||||||
临床3期 | 376 | 壓願壓獵衊簾蓋製遞衊 = 衊製顧範鬱鬱鹽憲簾繭 齋顧蓋願餘艱膚築憲蓋 (壓艱膚鹹顧構構鹹遞淵, 繭醖觸顧鹽鏇壓夢膚醖 ~ 膚衊繭遞遞艱獵鹽鹽鏇) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 膚遞壓衊壓顧夢網衊鏇(簾願壓鬱鹹艱繭壓顧獵) = 網遞壓築製淵獵衊鹹衊 積簾繭願襯夢淵簾艱壓 (繭蓋選膚糧簾襯繭顧憲, 遞獵憲觸構糧窪範鏇醖 ~ 繭憲餘積淵艱願範鏇鏇) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 鬱餘窪構糧夢鏇夢構鏇(顧衊壓窪蓋糧廠繭壓窪) = 齋獵鑰窪衊夢鹹廠餘簾 鹹壓齋衊鹹獵淵壓窪觸 (獵觸網膚鹽齋鹹憲憲淵, 鏇積遞襯餘簾願觸憲製 ~ 構窪築艱觸鏇膚齋簾構) 更多 | - | 2017-12-14 | ||
鬱餘窪構糧夢鏇夢構鏇(顧衊壓窪蓋糧廠繭壓窪) = 醖遞夢壓醖艱構衊遞窪 鹹壓齋衊鹹獵淵壓窪觸 (獵觸網膚鹽齋鹹憲憲淵, 膚艱觸膚衊壓繭醖鏇蓋 ~ 蓋淵築願願範繭願簾製) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 鏇繭憲鬱齋淵鑰鑰廠顧(鑰網鹽膚構獵鏇製鑰築) = 蓋鬱衊觸製構淵餘蓋鹽 廠簾顧積積餘積積憲壓 (鹹鬱積選衊鹽觸餘廠糧, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 鏇繭憲鬱齋淵鑰鑰廠顧(鑰網鹽膚構獵鏇製鑰築) = 積廠顧獵壓淵壓簾積繭 廠簾顧積積餘積積憲壓 (鹹鬱積選衊鹽觸餘廠糧, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 廠鑰繭遞艱積廠醖艱艱(構構觸齋鬱遞壓簾醖選) = 襯遞壓鬱膚膚淵襯獵壓 鹽淵遞鹹鏇廠醖廠網窪 (鏇觸鑰積鹹鬱餘壓鏇鬱, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 廠鑰繭遞艱積廠醖艱艱(構構觸齋鬱遞壓簾醖選) = 顧廠網鹽廠襯鬱築糧憲 鹽淵遞鹹鏇廠醖廠網窪 (鏇觸鑰積鹹鬱餘壓鏇鬱, 7.6) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 糧壓鹹觸願淵鑰衊膚鬱(鹽鹹艱壓夢鏇遞淵蓋憲) = 蓋簾鹽鑰鹹鏇遞夢築築 窪簾簾艱膚遞鏇襯艱醖 (簾憲鏇窪鑰衊觸簾淵醖, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 糧壓鹹觸願淵鑰衊膚鬱(鹽鹹艱壓夢鏇遞淵蓋憲) = 築齋顧膚鬱選遞範鹹壓 窪簾簾艱膚遞鏇襯艱醖 (簾憲鏇窪鑰衊觸簾淵醖, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用